190 related articles for article (PubMed ID: 22997300)
1. Infectious disease. An enterprising time for HIV vaccine research.
Cohen J
Science; 2012 Sep; 337(6101):1446. PubMed ID: 22997300
[No Abstract] [Full Text] [Related]
2. HIV vaccine development--improving on natural immunity.
Johnston MI; Fauci AS
N Engl J Med; 2011 Sep; 365(10):873-5. PubMed ID: 21899447
[No Abstract] [Full Text] [Related]
3. AIDS research. Novel antibody response may explain HIV vaccine success.
Cohen J
Science; 2011 Sep; 333(6049):1560. PubMed ID: 21921167
[No Abstract] [Full Text] [Related]
4. The RV144 Thai HIV vaccine trial.
Plotkin SA
Hum Vaccin; 2010 Feb; 6(2):159. PubMed ID: 20431337
[No Abstract] [Full Text] [Related]
5. HIV/AIDS research. Potent HIV antibodies spark vaccine hopes.
Cohen J
Science; 2009 Sep; 325(5945):1195. PubMed ID: 19729632
[No Abstract] [Full Text] [Related]
6. RV144: old vs. new.
Weiner DB
Hum Vaccin; 2010 Feb; 6(2):159-61. PubMed ID: 20431335
[No Abstract] [Full Text] [Related]
7. HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem.
Koff WC
Vaccine; 2012 Jun; 30(29):4310-5. PubMed ID: 22100891
[TBL] [Abstract][Full Text] [Related]
8. Challenges and opportunities for development of an AIDS vaccine.
Nabel GJ
Nature; 2001 Apr; 410(6831):1002-7. PubMed ID: 11309631
[TBL] [Abstract][Full Text] [Related]
9. Current world literature.
Curr Opin HIV AIDS; 2009 Sep; 4(5):453-7. PubMed ID: 20046137
[No Abstract] [Full Text] [Related]
10. HIV surface proteins finally caught going au naturel.
Cohen J
Science; 2013 Nov; 342(6158):546-7. PubMed ID: 24179198
[No Abstract] [Full Text] [Related]
11. Selection of human anti-HIV broadly neutralizing antibodies occurs within the context of frozen 1F7-idiotypic repertoire.
Parsons MS; Rouleau D; Routy JP; LeBlanc R; Grant MD; Bernard NF
AIDS; 2011 Jun; 25(10):1249-64. PubMed ID: 21516028
[TBL] [Abstract][Full Text] [Related]
12. The 2017 Keystone Symposium on HIV Vaccines.
Cottrell CA; Ward AB
Hum Vaccin Immunother; 2017 Oct; 13(10):2348-2351. PubMed ID: 28786733
[No Abstract] [Full Text] [Related]
13. HIV Vaccines: One Step Closer.
Low MSY; Tarlinton D
Trends Mol Med; 2017 Jan; 23(1):1-3. PubMed ID: 27889424
[TBL] [Abstract][Full Text] [Related]
14. In vivo protection by broadly neutralizing HIV antibodies.
van Gils MJ; Sanders RW
Trends Microbiol; 2014 Oct; 22(10):550-1. PubMed ID: 25169020
[TBL] [Abstract][Full Text] [Related]
15. Vaccine-induced HIV seropositivity: a problem on the rise.
Van Braeckel E; Koutsoukos M; Bourguignon P; Clement F; McNally L; Leroux-Roels G
J Clin Virol; 2011 Apr; 50(4):334-7. PubMed ID: 21300566
[TBL] [Abstract][Full Text] [Related]
16. Tiny steps towards an HIV vaccine.
Willyard C
Nature; 2010 Jul; 466(7304):S8. PubMed ID: 20631706
[No Abstract] [Full Text] [Related]
17. As antibody findings mount, what comes next? Interview by Kristen Jill Kresge and Regina McEnery.
Burton D; Mascola J; Michael N; Overbaugh J
IAVI Rep; 2011; 15(1):4-7. PubMed ID: 21449503
[No Abstract] [Full Text] [Related]
18. Development of vaccination strategies that elicit broadly neutralizing antibodies against human immunodeficiency virus type 1 in both the mucosal and systemic immune compartments.
Hone DM; DeVico AL; Fouts TR; Onyabe DY; Agwale SM; Wambebe CO; Blattner WA; Gallo RC; Lewis GK
J Hum Virol; 2002; 5(1):17-23. PubMed ID: 12352264
[TBL] [Abstract][Full Text] [Related]
19. Structure-function in HIV research. Interview by Simon Noble.
Burton D
IAVI Rep; 2007; 11(1):10-3. PubMed ID: 20210120
[No Abstract] [Full Text] [Related]
20. AIDS/HIV. A boost for HIV vaccine design.
Burton DR; Weiss RA
Science; 2010 Aug; 329(5993):770-3. PubMed ID: 20705840
[No Abstract] [Full Text] [Related]
[Next] [New Search]
